torcetrapib has been researched along with Hyperlipoproteinemia Type II in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (83.33) | 29.6817 |
2010's | 1 (16.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Catalano, G; Chapman, MJ; Fournier, N; Frisdal, E; Guerin, M; Julia, Z; Le Goff, W; Vedie, B | 1 |
Bots, ML; Dogan, S; Duivenvoorden, R; Evans, GW; Grobbee, DE; Kastelein, JJ; Shear, CL; Visseren, FL | 1 |
Barter, PJ; Bots, ML; Burgess, L; Duggan, WT; Evans, GW; Grobbee, DE; Kastelein, JJ; Kuivenhoven, JA; Revkin, JH; Riley, WA; Shear, CL; van Leuven, SI | 1 |
Bots, ML; Evans, GW; Kastelein, JJ; Revkin, JH; Riley, WA; Shear, CL; van Leuven, SI | 1 |
El Harchaoui, K; Kastelein, JJ; Stroes, ES; van der Steeg, WA | 1 |
Chapman, MJ; Duchene, E; Guerin, M; Julia, Z; Le Goff, W; Nguyen, T; Shear, CL; Thuren, T | 1 |
1 review(s) available for torcetrapib and Hyperlipoproteinemia Type II
Article | Year |
---|---|
The role of CETP inhibition in dyslipidemia.
Topics: Amides; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Dyslipidemias; Esters; Female; Humans; Hyperlipoproteinemia Type II; Hypertriglyceridemia; Male; Quinolines; Sulfhydryl Compounds | 2007 |
5 trial(s) available for torcetrapib and Hyperlipoproteinemia Type II
Article | Year |
---|---|
Torcetrapib differentially modulates the biological activities of HDL2 and HDL3 particles in the reverse cholesterol transport pathway.
Topics: Adult; Animals; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Cholesterol, HDL; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, HDL2; Lipoproteins, HDL3; Liver; Male; Mice; Mice, Inbred C57BL; Middle Aged; Pyrroles; Quinolines; Scavenger Receptors, Class B; Time Factors; Treatment Outcome | 2009 |
Ultrasound protocols to measure carotid intima-media thickness in trials; comparison of reproducibility, rate of progression, and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Carotid Artery, Internal; Disease Progression; Dyslipidemias; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Reproducibility of Results; Tunica Intima; Ultrasonography | 2010 |
Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Heterozygote; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines | 2007 |
Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis.
Topics: Adolescent; Adult; Aged; Algorithms; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Arteries; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Male; Middle Aged; Models, Biological; Pyrroles; Quinolines; Research Design; Tunica Intima; Ultrasonography | 2007 |
Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol Ester Transfer Proteins; Chylomicrons; Dietary Fats; Dietary Proteins; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, VLDL; Male; Middle Aged; Postprandial Period; Pyrroles; Quinolines | 2008 |